|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The programmed cell death protein-1/programmed cell death ligand 1 expression, CD3+ T cell infiltration, NY-ESO-1 expression, and microsatellite instability phenotype in primary cutaneous melanoma and mucosal melanoma and their clinical significance and prognostic value: a study of 89 consecutive cases.
|
31095042 |
2020 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Freshly prepared autologous NY-ESO-1-specific T-cell receptor (TCR) transgenic lymphocytes were adoptively transferred together with NY-ESO-1 peptide-pulsed DC vaccination in HLA-A2.1-positive subjects alone (ESO, NCT02070406) or with ipilimumab (INY, NCT01697527) in patients with advanced sarcoma or melanoma.
|
30573690 |
2019 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
NY-ESO-1, as the most targeted antigen type, is the target of 31 clinical trials; melanoma is the most targeted cancer type and is the target of 33 clinical trials.
|
30798772 |
2019 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We then confirmed this result in a second model with an HLA-DP4+ melanoma cell line that expresses a low amount of NY-ESO-1.
|
29399408 |
2018 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this phase I dose escalation study, we treated eight patients with high-risk surgically resected stage II-IV melanoma with intravenous autologous monocyte-derived DCs loaded with the NKT cell agonist α-GalCer and peptides derived from the cancer testis antigen NY-ESO-1.
|
29094183 |
2018 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Retrospective data suggested a higher clinical benefit of ipilimumab in melanoma patients with preexisting NY-ESO-1-specific immunity.
|
29306769 |
2018 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data support the continued investigation of adjuvant NY-ESO-1 based immunotherapy regimens in melanoma.
|
29773080 |
2018 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we used the human tumor antigen NY-ESO-1 (ESO) and the human leukocyte antigen variant HLA-A*0201 (A2) as a model and predicted <i>in silico</i> the 41 highest-affinity, A2-binding 8-11-mer peptides and assessed their binding, kinetic complex stability, and immunogenicity in A2-transgenic mice and on peripheral blood mononuclear cells from ESO-vaccinated melanoma patients.
|
28536262 |
2017 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, both elevated NY-ESO-1 release and macroautophagy targeting could improve melanoma cell recognition by CD4(+) T cells and should be explored during immunotherapy of melanoma.
|
26608910 |
2016 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results demonstrated higher expression of MAGE-A compared with NY-ESO-1 in melanomas (32% vs. 13%) and squamous cell carcinomas (45% vs. 7.9%), and higher expression of both CTAs in metastatic versus primary tumors.
|
26641256 |
2016 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
DN CAR T cells lysed native tumor targets <i>in vitro</i>, and, in a xenogeneic mouse model implanted with two human melanoma lines (A2+/NYESO+ and A2+/NYESO-), DN CAR T cells specifically migrated to, and delayed progression of, only the HLA-A2+/NY-ESO-1+ melanoma.
|
29675462 |
2016 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
As a result, therapy with CL-14-NY-ESO-1 together with anti-CTLA-4 is highly effective in controlling the development of an established melanoma.
|
25403749 |
2015 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The adoptive transfer of autologous T cells transduced with a retrovirus encoding a TCR against an HLA-A*0201 restricted NY-ESO-1 epitope can be an effective therapy for some patients bearing synovial cell sarcomas and melanomas that are refractory to other treatments.
|
25538264 |
2015 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
HLA-A2-restricted TCR-transduced (TD) CIK directed against the melanoma antigens Mart1 and NY-ESO1 were generated by lentiviral transduction and successfully expanded over a 3-4-week period.
|
25758764 |
2015 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
NY-ESO-1 specific antibody and cellular responses in melanoma patients primed with NY-ESO-1 protein in ISCOMATRIX and boosted with recombinant NY-ESO-1 fowlpox virus.
|
25081390 |
2015 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We illustrated the usage of our platform by monitoring the response of a melanoma patient cohort to an experimental therapeutic NY-ESO-1-based cancer vaccine; inter alia, we found evidence of determinant spreading in individual patients, as well as differential CT antigen expression and epitope usage.
|
24604332 |
2014 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tumor regression has been observed following transfer of T cells engineered to express chimeric antigen receptors against CD19 in B-cell malignancies or a T-cell receptor against NY-ESO-1 in synovial cell sarcoma and melanoma.
|
24329789 |
2014 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Similarly, impressive clinical responses were seen in melanoma and synovial cell carcinoma with TCR-modified T cells redirected against the melanocyte lineage antigen MART-1 and the testis-cancer antigen NY-ESO-1.
|
23804078 |
2013 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Integrated NY-ESO-1-specific antibody and CD4(+) and CD8(+) T cells were induced in a high proportion of melanoma and EOC patients.
|
22454499 |
2012 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Importantly, we found that parasites expressing a cancer testis antigen (NY-ESO-1) were able to elicit human antigen-specific T-cell responses in vitro and solid protection against melanoma in a mouse model.
|
22114198 |
2011 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we studied T cell receptor (TCR) primary structure and function of 605 HLA-A*0201/NY-ESO-1(157-165)-specific CD8 T cell clones derived from five melanoma patients.
|
18809922 |
2008 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
Primary MMs expressing NY-ESO-1 were significantly thicker than NY-ESO-1 negative cases (median thickness 4.7 mm versus 1.53 mm respectively, P = 0.03).
|
17625806 |
2007 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tumor-associated antigens (TAAs) have been the most actively employed targets in the clinical diagnosis and treatment of human carcinoma, such as PSA in the diagnosis of prostate cancer and NY-ESO-1 in the immunotherapy of melanoma and other cancers.
|
16381942 |
2006 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Molecular analyses demonstrated a de novo long-lasting expression of the CTA MAGE-1, -2, -3, -4, -10, GAGE 1-6, NY-ESO-1, and the upregulation of MAGE-1, MAGE-3, and NY-ESO-1 levels in melanoma xenografts from 5-AZA-CdR-treated mice.
|
16252259 |
2006 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
NY-ESO-1 specific Ab present in the sera of patients with melanoma, prostate cancer, nonsmall cell lung cancer, esophageal cancer, gastric cancer and hepatocellular carcinoma reacted with the dominant peptide at a similar frequency as the recombinant protein.
|
15540228 |
2005 |